

Literatura

1. Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study. *Lancet* 2015; 385(9974): 1206–1218. doi: 10.1016/S0140-6736(14)61396-9.
2. De Angelis R, Sant M, Coleman MP et al. Cancer survival in Europe 1999–2007 by country and age: results of EURO CARE-5 – a population-based study. *Lancet Oncol* 2014; 15(1): 23–34. doi: 10.1016/S1470-2045(13)70546-1.
3. Španielová H. Viry, které uzdravují. *Vesmír* 2010; 89(3): 181–183.
4. Mozaffari Nejad AS, Noor T, Munim ZH et al. A bibliometric review of oncolytic virus research as a novel approach for cancer therapy. *Virology* 2021; 18(1): 98. doi: 10.1186/s12985-021-01571-7.
5. Kuryk L, Vassilev L, Ranki T et al. Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – support for clinical studies on advanced cancer treatment. *PloS One* 2017; 12(8): e0182715. doi: 10.1371/journal.pone.0182715.
6. Santry LA, van Vloten JP, Knapp JP et al. Tumour vasculature: friend or foe of oncolytic viruses? *Cytokine Growth Factor Rev* 2020; 56: 69–82. doi: 10.1016/j.cytogfr.2020.07.007.
7. Rahman MM, McFadden G. Oncolytic viruses: newest frontier for cancer immunotherapy. *Cancers* 2021; 13(21): 5452. doi: 10.3390/cancers13215452.
8. Humeau J, Le Naour J, Galluzzi L et al. Trial watch: intratumoral immunotherapy. *Oncoimmunology* 2021; 10(1): 1984677. doi: 10.1080/2162402X.2021.1984677.
9. Roy DG, Geoffroy K, Marguerie M et al. Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination. *Nat Commun* 2021; 12(1): 2626. doi: 10.1038/s41467-021-22929-z.
10. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. *Nat Rev Drug Discov* 2015; 14(9): 642–662. doi: 10.1038/nrd4663.
11. Elvington M, Liszewski MK, Atkinson JP. CD46 and oncologic interactions: friendly fire against cancer. *Antibodies* 2020; 9(4): 59. doi: 10.3390/antib9040059.
12. Fernandes J. Oncogenes: the passport for viral oncolysis through PKR inhibition. *Biomark Cancer* 2016; 8: 101–110. doi: 10.4137/BIC.S33378.
13. Jhawar SR, Thandoni A, Bommareddy PK et al. Oncolytic viruses – natural and genetically engineered cancer immunotherapies. *Front Oncol* 2017; 7: 202. doi: 10.3389/fonc.2017.00202.
14. Verheije MH, Rottier PJM. Retargeting of viruses to generate oncolytic agents. *Adv Virol* 2012; 2012: 798526. doi: 10.1155/2012/798526.
15. O’Shea C, Miyake-Stoner SJ, Powers CJ et al. Highly selective and potent p16-CDK-RB-E2F targeted oncolytic virus therapies. *J Clin Oncol* 2021; 39(Suppl 15): e14543–e14543. doi: 10.1200/JCO.2021.39.15_suppl.e14543.
16. Pascual-Pasto G, Bazan-Peregrino M, Olaciregui NG et al. Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. *Sci Transl Med* 2019; 11(476): eaat9321. doi: 10.1126/scitranslmed.aat9321.
17. Kawashima T, Kagawa S, Kobayashi N et al. Telomerase-specific replication-selective virotherapy for human cancer. *Clin Cancer Res* 2004; 10(1): 285–292. doi: 10.1158/1078-0432.CCR-1075-3.
18. Chaurasiya S, Fong Y, Warner SG. Optimizing oncolytic viral design to enhance antitumor efficacy: progress and challenges. *Cancers* 2020; 12(6): 1699. doi: 10.3390/cancers12061699.
19. Pol JG, Workenhe ST, Konda P et al. Cytokines in oncolytic virotherapy. *Cytokine Growth Factor Rev* 2020; 56: 4–27. doi: 10.1016/j.cytogfr.2020.10.007.

20. Heidbuechel JPW, Engeland CE. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies. *J Hematol Oncol* 2021; 14(1): 63. doi: 10.1186/s13045-021-01075-5.
21. Kontermann RE, Ungerechts G, Nettelbeck DM. Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics. *MAbs* 2021; 13(1): 1982447. doi: 10.1080/19420862.2021.1982447.
22. Freedman JD, Duffy MR, Lei-Rossmann J et al. An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells. *Cancer Res* 2018; 78(24): 6852–6865. doi: 10.1158/0008-5472.CAN-18-1750.
23. Bořilová S, Grell P, Bílek O et al. Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors. *Onkologie* 2020; 14(5): 205–212. doi: 10.36290/xon.2020.075.
24. McGray AJR, Huang R-Y, Battaglia S et al. Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer. *J Immunother Cancer* 2019; 7(1): 189. doi: 10.1186/s40425-019-0641-x.
25. Mihályová J, Jelínek T, Kaščák M et al. Practical aspects of CAR-T cell therapy. *Klin Onkol* 2022; 35(1): 44–54. doi: 10.48095/ccko202244.
26. Aalipour A, Le Boeuf F, Tang M et al. Viral delivery of CAR targets to solid tumors enables effective cell therapy. *Mol Ther Oncolytics* 2020; 17: 232–240. doi: 10.1016/j.omto.2020.03.018.
27. Ferguson MS, Lemoine NR, Wang Y. Systemic delivery of oncolytic viruses: hopes and hurdles. *Adv Virol* 2012; 2012: e805629. doi: 10.1155/2012/805629.
28. Xu W, Atkinson VG, Menzies AM. Intratumoural immunotherapies in oncology. *Eur J Cancer* 2020; 127: 1–11. doi: 10.1016/j.ejca.2019.12.007.
29. Koski A, Bramante S, Kipar A et al. Biodistribution analysis of oncolytic adenoviruses in patient autopsy samples reveals vascular transduction of noninjected tumors and tissues. *Mol Ther* 2015; 23(10): 1641–1652. doi: 10.1038/mt.2015.125.
30. Dal Corso A, Pignataro L, Belvisi L et al. Innovative linker strategies for tumor-targeted drug conjugates. *Chemistry* 2019; 25(65): 14740–14757. doi: 10.1002/chem.201903127.
31. Garofalo M, Bellato F, Magliocca S et al. Polymer coated oncolytic adenovirus to selectively target hepatocellular carcinoma cells. *Pharmaceutics* 2021; 13(7): 949. doi: 10.3390/pharmaceutics13070949.
32. Sewald X, Motamedi N, Mothes W. Viruses exploit the tissue physiology of the host to spread in vivo. *Curr Opin Cell Biol* 2016; 41: 81–90. doi: 10.1016/j.ceb.2016.04.008.
33. Reale A, Calistri A, Altomonte J. Giving oncolytic viruses a free ride: carrier cells for oncolytic virotherapy. *Pharmaceutics* 2021; 13(12): 2192. doi: 10.3390/pharmaceutics13122192.
34. Aldrak N, Alsaab S, Algethami A et al. Oncolytic herpes simplex virus-based therapies for cancer. *Cells* 2021; 10(6): 1541. doi: 10.3390/cells10061541.
35. Cunliffe TG, Bates EA, Parker AL. Hitting the target but missing the point: recent progress towards adenovirus-based precision virotherapies. *Cancers* 2020; 12(11): 3327. doi: 10.3390/cancers12113327.
36. Chan WM, McFadden G. Oncolytic poxviruses. *Annu Rev Virol* 2014; 1(1): 119–141. doi: 10.1146/annurev-virology-031413-085442.
37. Alberts P, Tilgase A, Rasa A et al. The advent of oncolytic virotherapy in oncology: the Rigvir® story. *Eur J Pharmacol* 2018; 837: 117–126. doi: 10.1016/j.ejphar.2018.08.042.
38. Alberts P. Comment on McCarthy, C.; et al. Developing picornaviruses for cancer therapy. *Cancers* 2019, 11, 685. *Cancers* 2020; 12(7): 1775. doi: 10.3390/cancers12071775.

39. State Agency of Medicines Republic of Latvia. Rigvir marketing authorisation suspended; information for current patients. [online]. Dostupné z: <https://www.zva.gov.lv/en/news-and-publications/news/rigvir-marketing-authorisation-suspended-information-current-patients>.
40. Liang M. Oncorine, the world first oncolytic virus medicine and its update in China. *Curr Cancer Drug Targets* 2018; 18(2): 171–176. doi: 10.2174/1568009618666171129221503.
41. Ferrucci PF, Pala L, Conforti F et al. Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. *Cancers* 2021; 13(6): 1383. doi: 10.3390/cancers13061383.
42. Shen Y, Nemunaitis J. Herpes simplex virus 1 (HSV-1) for cancer treatment. *Cancer Gene Ther* 2006; 13(11): 975–992. doi: 10.1038/sj.cgt.7700946.
43. Sugawara K, Iwai M, Ito H et al. Oncolytic herpes virus G47 Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation. *Mol Ther Oncolytics* 2021; 22: 129–142. doi: 10.1016/j.omto.2021.05.004.
44. Taguchi S, Fukuhara H, Todo T. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives. *Jpn J Clin Oncol* 2019; 49(3): 201–209. doi: 10.1093/jjco/hyy170.
45. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; 136(5): E359–E386. doi: 10.1002/ijc.29210.
46. Lawler SE, Speranza M-C, Cho C-F et al. Oncolytic viruses in cancer treatment: a review. *JAMA Oncol* 2017; 3(6): 841–849. doi: 10.1001/jamaoncol.2016.2064.
47. Chaurasiya S, Fong Y. Viroimmunotherapy for breast cancer: promises, problems and future directions. *Cancer Gene Ther* 2021; 28(7–8): 757–768. doi: 10.1038/s41417-020-00265-6.
48. Zhang H, Xie W, Zhang Y et al. Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model. *Cancer Gene Ther* 2021; 29(5): 1–10. doi: 10.1038/s41417-021-00389-3.
49. Xie R, Bi X, Shang B et al. Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis. *Virology* 2021; 18(1): 158. doi: 10.1186/s12985-021-01630-z.
50. Carter ME, Koch A, Lauer UM et al. Clinical trials of oncolytic viruses in breast cancer. *Front Oncol* 2021; 11: 803050. doi: 10.3389/fonc.2021.803050.
51. Bernstein V, Ellard SL, Dent SF et al. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. *Breast Cancer Res Treat* 2018; 167(2): 485–493. doi: 10.1007/s10549-017-4538-4.
52. Hall BL, Leroni D, Miyagawa Y et al. Generation of an oncolytic herpes simplex viral vector completely retargeted to the GDNF receptor GFR α 1 for specific infection of breast cancer cells. *Int J Mol Sci* 2020; 21(22): 8815. doi: 10.3390/ijms21228815.
53. Annels NE, Simpson GR, Denyer M et al. Oncolytic reovirus-mediated recruitment of early innate immune responses reverses immunotherapy resistance in prostate tumors. *Mol Ther Oncolytics* 2021; 20: 434–446. doi: 10.1016/j.omto.2020.09.010.
54. Boettcher AN, Usman A, Morgans A et al. Past, current, and future of immunotherapies for prostate cancer. *Front Oncol* 2019; 9: 884. doi: 10.3389/fonc.2019.00884.
55. Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion through loss of MHC class I antigen presentation. *Front Immunol* 2021; 12: 636568. doi: 10.3389/fimmu.2021.636568.
56. Liu Y-T, Sun Z-J. Turning cold tumors into hot tumors by improving T-cell infiltration. *Theranostics* 2021; 11(11): 5365–5386. doi: 10.7150/thno.58390.

57. Zhao H, Wu L, Yan G et al. Inflammation and tumor progression: signaling pathways and targeted intervention. *Signal Transduct Target Ther* 2021; 6(1): 1–46. doi: 10.1038/s41392-021-00658-5.
58. Patel D, McKay R, Parsons JK. Immunotherapy for localized prostate cancer: the next frontier? *Urol Clin North Am* 2020; 47(4): 443–456. doi: 10.1016/j.ucl.2020.07.008.
59. Adamaki M, Zoumpourlis V. Immunotherapy as a precision medicine tool for the treatment of prostate cancer. *Cancers* 2021; 13(2): 173. doi: 10.3390/cancers13020173.
60. Cheng H, Wang Y, Liu C et al. Development and verification of a prostate cancer prognostic signature based on an immunogenomic landscape analysis. *Front Oncol* 2021; 11: 711258. doi: 10.3389/fonc.2021.711258.
61. Eigel BJ, Chi K, Tu D et al. A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. *Oncotarget* 2018; 9(8): 8155–8164. doi: 10.18632/oncotarget.24263.
62. Singh P, Pal SK, Alex A et al. Development of PROSTVAC immunotherapy in prostate cancer. *Future Oncol* 2015; 11(15): 2137–2148. doi: 10.2217/fon.15.120.
63. Gulley JL, Borre M, Vogelzang NJ et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. *J Clin Oncol* 2019; 37(13): 1051–1061. doi: 10.1200/JCO.18.02031.
64. Zhu H, Liu X. Advances of tumorigenesis, diagnosis at early stage, and cellular immunotherapy in gastrointestinal malignancies. *Front Oncol* 2021; 11: 666340. doi: 10.3389/fonc.2021.666340.
65. Russo M, Sogari A, Bardelli A. Adaptive evolution: how bacteria and cancer cells survive stressful conditions and drug treatment. *Cancer Discov* 2021; 11(8): 1886–1895. doi: 10.1158/2159-8290.CD-20-1588.
66. Russo M, Crisafulli G, Sogari A et al. Adaptive mutability of colorectal cancers in response to targeted therapies. *Science* 2019; 366(6472): 1473–1480. doi: 10.1126/science.aav4474.
67. Kim CW, Chon HJ, Kim C. Combination immunotherapies to overcome intrinsic resistance to checkpoint blockade in microsatellite stable colorectal cancer. *Cancers* 2021; 13(19): 4906. doi: 10.3390/cancers13194906.
68. Geevarghese SK, Geller DA, de Haan HA et al. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. *Hum Gene Ther* 2010; 21(9): 1119–1128. doi: 10.1089/hum.2010.020.
69. Hu J, Lu R, Zhang Y et al. β -adrenergic receptor inhibition enhances oncolytic herpes virus propagation through STAT3 activation in gastric cancer. *Cell Biosci* 2021; 11(1): 174. doi: 10.1186/s13578-021-00687-1.
70. Ilyas FZ, Beane JD, Pawlik TM. The state of immunotherapy in hepatobiliary cancers. *Cells* 2021; 10(8): 2096. doi: 10.3390/cells10082096.
71. Zhang B, Huang J, Tang J et al. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial. *J Immunother Cancer* 2021; 9(4): e002224. doi: 10.1136/jitc-2020-002224.
72. Xia Z-J, Chang J-H, Zhang L et al. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. *Ai Zheng* 2004; 23(12): 1666–1670.
73. Ekeke CN, Russell KL, Joubert K et al. Fighting fire with fire: oncolytic virotherapy for thoracic malignancies. *Ann Surg Oncol* 2021; 28(5): 2715–2727. doi: 10.1245/s10434-020-09477-4.
74. Schenk EL, Mandrekar SJ, Dy GK et al. A randomized double-blind phase II study of the seneca valley virus (NTX-010) versus placebo for patients with extensive-stage SCLC (ES

- SCLC) who were stable or responding after at least four cycles of platinum-based chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study. *J Thorac Oncol* 2020; 15(1): 110–119. doi: 10.1016/j.jtho.2019.09.083.
75. Zhang H, Qin L, Li C et al. Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy combined with ganciclovir induces hepatoma cell apoptosis. *Exp Ther Med* 2019; 17(3): 1649–1655. doi: 10.3892/etm.2019.7147.
76. Powell SF, Patel MR, Merchan J et al. VSV-IFN β -NIS intratumoral (IT) injection: a first-in-human (FIH), phase I study of an innovative oncolytic virotherapy, alone and with an anti-PD-L1 antibody, in patients with refractory solid tumors. *Ann Oncol* 2018; 29(Suppl 8): viii439. doi: 10.1093/annonc/mdy288.108.
77. Felt SA, Grdzeliashvili VZ. Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update. *J Gen Virol* 2017; 98(12): 2895–2911. doi: 10.1099/jgv.0.000980.
78. Pol JG, Acuna SA, Yadollahi B et al. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. *Oncoimmunology* 2018; 8(1): e1512329. doi: 10.1080/2162402X.2018.1512329.
79. Shi Z, Liu B, Huang C et al. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy. *Biochem Biophys Res Commun* 2021; 559: 176–182. doi: 10.1016/j.bbrc.2021.04.078.
80. Wadowski B, Bueno R, De Rienzo A. Immune microenvironment and genetics in malignant pleural mesothelioma. *Front Oncol* 2021; 11: 684025. doi: 10.3389/fonc.2021.684025.
81. Zaheer U, Hassain NA, Banu S et al. Oncolytic viruses as nanomedicines against the tumor microenvironment. *Biointerface Res Appl Chem* 2021; 11(6): 14825–14852. doi: 10.33263/BRIAC116.1482514852.
82. Zhang Q, Li Y, Zhao Q et al. Recombinant human adenovirus type 5 (Oncorine) reverses resistance to immune checkpoint inhibitor in a patient with recurrent non-small cell lung cancer: a case report. *Thorac Cancer* 2021; 12(10): 1617–1619. doi: 10.1111/1759-7714.13947.
83. Liang Y, Tian W-Y, Huang J-J et al. MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells. *Oncol Lett* 2021; 21(6): 482. doi: 10.3892/ol.2021.12743.
84. Alvanegh AG, Ganji SM, Kamel A et al. Comparison of oncolytic virotherapy and nanotherapy as two new miRNA delivery approaches in lung cancer. *Biomed Pharmacother* 2021; 140: 111755. doi: 10.1016/j.biopha.2021.111755.
85. Ballman KV, Buckner JC, Brown PD et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. *Neuro Oncol* 2007; 9(1): 29–38. doi: 10.1215/15228517-2006-025.
86. Todo T, Ito H, Ino Y et al. Intratumoral oncolytic herpes virus G47 Δ for residual or recurrent glioblastoma: a phase 2 trial. *Nat Med* 2022; 28(8): 1630–1639. doi: 10.1038/s41591-022-01897-x.
87. FDA. FDA's orphan drug designation to toca 511 & toca FC for glioblastoma. *Oncol Times* 2015; 37(18): 57. doi: 10.1097/01.COT.0000471997.28149.68.
88. Tocagen Inc. A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma. clinicaltrials.gov; 2020.

89. Collins SA, Shah AH, Ostertag D et al. Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer. *Expert Opin Biol Ther* 2021; 21(9): 1199–1214. doi: 10.1080/14712598.2021.1902982.
90. Angelova A, Ferreira T, Bretscher C et al. Parvovirus-based combinatorial immunotherapy: a reinforced therapeutic strategy against poor-prognosis solid cancers. *Cancers* 2021; 13(2): 342. doi: 10.3390/cancers13020342.
91. Kicieliński KP, Chiocca EA, Yu JS et al. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. *Mol Ther* 2014; 22(5): 1056–1062. doi: 10.1038/mt.2014.21.
92. Carpenter AB, Carpenter AM, Aiken R et al. Oncolytic virus in gliomas: a review of human clinical investigations. *Ann Oncol* 2021; 32(8): 968–982. doi: 10.1016/j.annonc.2021.03.197.
93. Cohn DE, Sill MW, Walker JL et al. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: an NRG Oncology/Gynecologic Oncology Group Study. *Gynecol Oncol* 2017; 146(3): 477–483. doi: 10.1016/j.ygyno.2017.07.135.
94. Doo DW, Norian LA, Arend RC. Checkpoint inhibitors in ovarian cancer: a review of preclinical data. *Gynecol Oncol Rep* 2019; 29: 48–54. doi: 10.1016/j.gore.2019.06.003.
95. de Queiroz NMGP, Xia T, Konno H et al. Ovarian cancer cells commonly exhibit defective STING signaling which affects sensitivity to viral oncolysis. *Mol Cancer Res* 2019; 17(4): 974–986. doi: 10.1158/1541-7786.MCR-18-0504.
96. Cornejo Y, Li M, Dellinger TH et al. NSCs are permissive to oncolytic Myxoma virus and provide a delivery method for targeted ovarian cancer therapy. *Oncotarget* 2020; 11(51): 4693–4698. doi: 10.18632/oncotarget.27845.
97. Yue E, Yang G, Yao Y et al. Targeting CA-125 transcription by development of a conditionally replicative adenovirus for ovarian cancer treatment. *Cancers* 2021; 13(17): 4265. doi: 10.3390/cancers13174265.
98. van den Pol AN, Zhang X, Lima E et al. Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response. *Virology* 2021; 555: 44–55. doi: 10.1016/j.virol.2020.10.009.
99. Budzik KM, Nace RA, Ikeda Y et al. Oncolytic foamy virus: generation and properties of a nonpathogenic replicating retroviral vector system that targets chronically proliferating cancer cells. *J Virol* 2021; 95(10): e00015–e00021. doi: 10.1128/JVI.00015-21.
100. Manyam M, Stephens AJ, Kennard JA et al. A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer. *Gynecol Oncol* 2021; 163(3): 481–489. doi: 10.1016/j.ygyno.2021.10.069.
101. Moreno V, Barretina-Ginesta M-P, García-Donas J et al. Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. *J Immunother Cancer* 2021; 9(12): e003645. doi: 10.1136/jitc-2021-003645.
102. Chieffi P, De Martino M, Esposito F. New anti-cancer strategies in testicular germ cell tumors. *Recent Pat Anticancer Drug Discov* 2019; 14(1): 53–59. doi: 10.2174/1574892814666190111120023.
103. BioSpace. Oncolytics biotech Inc. announces issuance of 14th U.S. patent. [online]. Dostupné z: <https://www.biospace.com/article/oncolytics-biotech-inc-announces-issuance-of-14th-u-s-patent/>.
104. Morris D, Thompson BG, Coffey MC. Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions. *Calgary CA* 2012.

105. Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. *Oncoimmunology* 2015; 5(1): e1115641. doi: 10.1080/2162402X.2015.1115641.
106. Andtbacka RHI, Kaufman HL, Collichio F et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. *J Clin Oncol* 2015; 33(25): 2780–2788. doi: 10.1200/JCO.2014.58.3377.
107. Harrington KJ, Andtbacka RH, Collichio F et al. Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. *Onco Targets Ther* 2016; 9: 7081–7093. doi: 10.2147/OTT.S115245.
108. Státní ústav pro kontrolu léčiv. IMLYGIC. [online]. Dostupné z: <https://www.sukl.cz/modules/medication/detail.php?code=0209135&tab=texts>.
109. Kaufman HL, Shalhout SZ, Iodice G. Talimogene laherparepvec: moving from first-in-class to best-in-class. *Front Mol Biosci* 2022; 9: 834841. doi: 10.3389/fmolb.2022.834841.
110. van Akkooi ACJ, Haferkamp S, Papa S et al. A retrospective chart review study of real-world use of talimogene laherparepvec in unresectable stage IIIB–IVM1a melanoma in four European countries. *Adv Ther* 2021; 38(2): 1245–1262. doi: 10.1007/s12325-020-01590-w.
111. Randić T, Kozar I, Margue C et al. NRAS mutant melanoma: towards better therapies. *Cancer Treat Rev* 2021; 99: 102238. doi: 10.1016/j.ctrv.2021.102238.
112. Soldozy S, Mulligan KM, Zheng DX et al. Oncolytic virotherapy for melanoma brain metastases, a potential new treatment paradigm? *Brain Sci* 2021; 11(10): 1260. doi: 10.3390/brainsci11101260.
113. Proboka G, Tilgase A, Isajevs S et al. Melanoma unknown primary brain metastasis treatment with ECHO-7 oncolytic virus Rigvir: a case report. *Front Oncol* 2018; 8: 43. doi: 10.3389/fonc.2018.00043.
114. Alberts P, Olmane E, Brokāne L et al. Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient—three case reports. *APMIS* 2016; 124(10): 896–904. doi: 10.1111/apm.12576.
115. Tilgase A, Olmane E, Nazarovs J et al. Multimodality treatment of a colorectal cancer stage IV patient with FOLFOX-4, Bevacizumab, Rigvir oncolytic virus, and surgery. *Case Rep Gastroenterol* 2018; 12(2): 457–465. doi: 10.1159/000492210.
116. Valyi-Nagy T, Fredericks B, Ravindra A et al. Herpes simplex virus 1 infection promotes the growth of a subpopulation of tumor cells in three-dimensional uveal melanoma cultures. *J Virol* 2018; 92(19): e00700–e00718. doi: 10.1128/JVI.00700-18.
117. Davies K. The life oncolytic: an interview with Stephen J. Russell. *Hum Gene Ther* 2021; 32(3–4): 129–132. doi: 10.1089/hum.2021.29148.int.
118. Bais S, Bartee E, Rahman MM et al. Oncolytic virotherapy for hematological malignancies. *Adv Virol* 2012; 2012: 186512. doi: 10.1155/2012/186512.
119. Innao V, Rizzo V, Allegra AG et al. Oncolytic viruses and hematological malignancies: a new class of immunotherapy drugs. *Curr Oncol* 2020; 28(1): 159–183. doi: 10.3390/currenco128010019.
120. Ghanaat M, Goradel NH, Arashkia A et al. Virus against virus: strategies for using adenovirus vectors in the treatment of HPV-induced cervical cancer. *Acta Pharmacol Sin* 2021; 42(12): 1981–1990. doi: 10.1038/s41401-021-00616-5.
121. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol* 1999; 189(1): 12–19. doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.
122. Burman B, Pesci G, Zamarin D. Newcastle disease virus at the forefront of cancer immunotherapy. *Cancers* 2020; 12(12): 3552. doi: 10.3390/cancers12123552.

123. Keshavarz M, Ebrahimzadeh MS, Miri SM et al. Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment. *Virol J* 2020; 17(1): 64. doi: 10.1186/s12985-020-01326-w.
124. Taguchi S, Fukuhara H, Homma Y et al. Current status of clinical trials assessing oncolytic virus therapy for urological cancers. *Int J Urol* 2017; 24(5): 342–351. doi: 10.1111/iju.13325.
125. Wang H, Song L, Zhang X et al. Bluetongue viruses act as novel oncolytic viruses to effectively inhibit human renal cancer cell growth in vitro and in vivo. *Med Sci Monit* 2021; 27: e930634. doi: 10.12659/MSM.930634.
126. Park JS, Lee ME, Jang WS et al. Systemic injection of oncolytic vaccinia virus suppresses primary tumor growth and lung metastasis in metastatic renal cell carcinoma by remodeling tumor microenvironment. *Biomedicines* 2022; 10(1): 173. doi: 10.3390/biomedicines10010173.
127. Richters A, Aben KKH, Kiemeny LALM. The global burden of urinary bladder cancer: an update. *World J Urol* 2020; 38(8): 1895–1904. doi: 10.1007/s00345-019-02984-4.
128. Potts KG, Hitt MM, Moore RB. Oncolytic viruses in the treatment of bladder cancer. *Adv Urol* 2012; 2012: e404581. doi: 10.1155/2012/404581.
129. Hindupur SV, Schmid SC, Koch JA et al. STAT3/5 inhibitors suppress proliferation in bladder cancer and enhance oncolytic adenovirus therapy. *Int J Mol Sci* 2020; 21(3): 1106. doi: 10.3390/ijms21031106.
130. Hugar LA, Gilbert SM, Sexton WJ et al. Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer. *Curr Opin Urol* 2021; 31(2): 160–169. doi: 10.1097/MOU.0000000000000846.
131. Relph K, Annels N, Smith C et al. Oncolytic immunotherapy for bladder cancer using coxsackie A21 virus: using a bladder tumor precision-cut slice model system to assess viral efficacy. *Methods Mol Biol* 2020; 2058: 249–259. doi: 10.1007/978-1-4939-9794-7_16.
132. Shang C, Zhu Y-L, Li Y-Q et al. Autophagy promotes oncolysis of an adenovirus expressing apoptin in human bladder cancer models. *Invest New Drugs* 2021; 39(4): 949–960. doi: 10.1007/s10637-021-01073-x.
133. Hu J, Othmane B, Yu A et al. 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer. *BMC Med* 2021; 19(1): 289. doi: 10.1186/s12916-021-02163-6.
134. Nelson BE, Hong A, Jana B. Elucidation of novel molecular targets for therapeutic strategies in urothelial carcinoma: a literature review. *Front Oncol* 2021; 11: 705294. doi: 10.3389/fonc.2021.705294.
135. Chiu M, Armstrong EJL, Jennings V et al. Combination therapy with oncolytic viruses and immune checkpoint inhibitors. *Expert Opin Biol Ther* 2020; 20(6): 635–652. doi: 10.1080/14712598.2020.1729351.
136. Burke JM, Lamm DL, Meng MV et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. *J Urol* 2012; 188(6): 2391–2397. doi: 10.1016/j.juro.2012.07.097.
137. Gulley JL, Arlen PM, Tsang K-Y et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. *Clin Cancer Res* 2008; 14(10): 3060–3069. doi: 10.1158/1078-0432.CCR-08-0126.
138. Cheng G, Dong H, Yang C et al. A review on the advances and challenges of immunotherapy for head and neck cancer. *Cancer Cell Int* 2021; 21(1): 406. doi: 10.1186/s12935-021-02024-5.
139. Jones H, Green V, England J et al. Current understanding of nonsurgical interventions for refractory differentiated thyroid cancer: a systematic review. *Future Sci OA* 2021; 7(7): FSO738. doi: 10.2144/foa-2021-0041.

140. Gao P, Ding G, Wang L. The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis. *Transl Cancer Res* 2021; 10(10): 4290–4302. doi: 10.21037/tcr-21-905.
141. Lang FF, Conrad C, Gomez-Manzano C et al. Phase I study of DNX-2401 (delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. *J Clin Oncol* 2018; 36(14): 1419–1427. doi: 10.1200/JCO.2017.75.8219.
142. Oncolytics Biotech, Inc. [online]. Dostupné z: <https://www.oncolyticsbiotech.com>.
143. Halix. Get to know more about HALIX. [online]. Dostupné z: <https://www.halix.nl/about-halix/>.
144. Oncolys BioPharma. [online]. Dostupné z: <https://www.oncolys.com/en/>.
145. Kanaya N, Kuroda S, Kakiuchi Y et al. Immune modulation by telomerase-specific oncolytic adenovirus synergistically enhances antitumor efficacy with anti-PD1 antibody. *Mol Ther* 2020; 28(3): 794–804. doi: 10.1016/j.ymthe.2020.01.003.
146. International Virotherapy Center. [online]. Dostupné z: <https://www.virotherapy.com/about-ivc.php>.
147. CeGaT. About CeGaT. [online]. Dostupné z: <https://www.cegat.com/about-cegat/>.
148. Cervera-Carrascon V, Quixabeira DCA, Havunen R et al. Comparison of clinically relevant oncolytic virus platforms for enhancing T cell therapy of solid tumors. *Mol Ther Oncolytics* 2020; 17: 47–60. doi: 10.1016/j.omto.2020.03.003.
149. Kemp V, Lamfers MLM, van der Pluijm G et al. Developing oncolytic viruses for clinical use: a consortium approach. *Cytokine Growth Factor Rev* 2020; 56: 133–140. doi: 10.1016/j.cytogfr.2020.06.010.